\BOOKMARK [-1][-]{part.1}{I Notes}{}% 1
\BOOKMARK [0][-]{chapter.1}{Introduction}{part.1}% 2
\BOOKMARK [1][-]{section.1.1}{Genetics vs Genomics}{chapter.1}% 3
\BOOKMARK [2][-]{subsection.1.1.1}{Genetics}{section.1.1}% 4
\BOOKMARK [2][-]{subsection.1.1.2}{Genomics}{section.1.1}% 5
\BOOKMARK [2][-]{subsection.1.1.3}{Differences}{section.1.1}% 6
\BOOKMARK [2][-]{subsection.1.1.4}{Role of computational biology}{section.1.1}% 7
\BOOKMARK [1][-]{section.1.2}{Human Genomics - the Basis}{chapter.1}% 8
\BOOKMARK [2][-]{subsection.1.2.1}{Genetic Make-Up}{section.1.2}% 9
\BOOKMARK [2][-]{subsection.1.2.2}{Inherited variants' relevance}{section.1.2}% 10
\BOOKMARK [2][-]{subsection.1.2.3}{Differences in Genetic Make-Up, an example}{section.1.2}% 11
\BOOKMARK [2][-]{subsection.1.2.4}{Acquired DNA aberrations}{section.1.2}% 12
\BOOKMARK [1][-]{section.1.3}{Experimental techniques to detect variants/aberrations}{chapter.1}% 13
\BOOKMARK [2][-]{subsection.1.3.1}{Cariotyping}{section.1.3}% 14
\BOOKMARK [1][-]{section.1.4}{Sequence capture for cancer genomics}{chapter.1}% 15
\BOOKMARK [2][-]{subsection.1.4.1}{Single End \(SE\) and Paired End \(PE\) reads}{section.1.4}% 16
\BOOKMARK [-1][-]{part.2}{II Papers}{}% 17
\BOOKMARK [0][-]{chapter.2}{Role of non-coding sequence variants in cancer}{part.2}% 18
\BOOKMARK [1][-]{section.2.1}{Abstract}{chapter.2}% 19
\BOOKMARK [2][-]{subsection.2.1.1}{Introduction}{section.2.1}% 20
\BOOKMARK [1][-]{section.2.2}{Genomic sequence variants}{chapter.2}% 21
\BOOKMARK [1][-]{section.2.3}{Non-coding element annotation}{chapter.2}% 22
\BOOKMARK [2][-]{subsection.2.3.1}{Cis regulatory regions}{section.2.3}% 23
\BOOKMARK [2][-]{subsection.2.3.2}{Distal regulatory elements}{section.2.3}% 24
\BOOKMARK [2][-]{subsection.2.3.3}{RNA-seq}{section.2.3}% 25
\BOOKMARK [2][-]{subsection.2.3.4}{Transcribed pseudogenes}{section.2.3}% 26
\BOOKMARK [2][-]{subsection.2.3.5}{Evolutionary conservation}{section.2.3}% 27
\BOOKMARK [1][-]{section.2.4}{Roles for somatic variants in cancer}{chapter.2}% 28
\BOOKMARK [2][-]{subsection.2.4.1}{Gain of TF-binding sites}{section.2.4}% 29
\BOOKMARK [2][-]{subsection.2.4.2}{Fusion events due to genomic rearrangements}{section.2.4}% 30
\BOOKMARK [2][-]{subsection.2.4.3}{ncRNAs and their binding sites}{section.2.4}% 31
\BOOKMARK [2][-]{subsection.2.4.4}{Role of pseudogenes in modulating the expression of a parental gene}{section.2.4}% 32
\BOOKMARK [1][-]{section.2.5}{Roles for germline variants in cancer}{chapter.2}% 33
\BOOKMARK [2][-]{subsection.2.5.1}{Promoter mutations}{section.2.5}% 34
\BOOKMARK [2][-]{subsection.2.5.2}{SNPs in enhancers}{section.2.5}% 35
\BOOKMARK [2][-]{subsection.2.5.3}{Variants in introns}{section.2.5}% 36
\BOOKMARK [2][-]{subsection.2.5.4}{SNPs in ncRNA and their binding sites}{section.2.5}% 37
\BOOKMARK [2][-]{subsection.2.5.5}{Others}{section.2.5}% 38
\BOOKMARK [1][-]{section.2.6}{Interplay between germline and somatic variants}{chapter.2}% 39
\BOOKMARK [1][-]{section.2.7}{Computational methods for identifying variants}{chapter.2}% 40
\BOOKMARK [1][-]{section.2.8}{Experimental approaches for functional validation}{chapter.2}% 41
\BOOKMARK [0][-]{chapter.3}{Advances in understanding cancer genomics through second-generation sequencing}{part.2}% 42
\BOOKMARK [1][-]{section.3.1}{Abstract}{chapter.3}% 43
\BOOKMARK [2][-]{subsection.3.1.1}{Introduction}{section.3.1}% 44
\BOOKMARK [1][-]{section.3.2}{Cancer-specific consideration}{chapter.3}% 45
\BOOKMARK [2][-]{subsection.3.2.1}{Characteristics of cancer samples for genomic analysis}{section.3.2}% 46
\BOOKMARK [2][-]{subsection.3.2.2}{Structural variability of cancer genomes}{section.3.2}% 47
\BOOKMARK [1][-]{section.3.3}{Experimental approaches}{chapter.3}% 48
\BOOKMARK [2][-]{subsection.3.3.1}{Whole genome sequencing}{section.3.3}% 49
\BOOKMARK [2][-]{subsection.3.3.2}{Exome sequencing}{section.3.3}% 50
\BOOKMARK [2][-]{subsection.3.3.3}{Transcriptome sequencing}{section.3.3}% 51
\BOOKMARK [1][-]{section.3.4}{Detecting classes of genome alterations}{chapter.3}% 52
\BOOKMARK [2][-]{subsection.3.4.1}{Somatic nucleotide substitutions and small insertion and deletion mutations}{section.3.4}% 53
\BOOKMARK [2][-]{subsection.3.4.2}{Copy number}{section.3.4}% 54
\BOOKMARK [2][-]{subsection.3.4.3}{Chromosomal rearrangements}{section.3.4}% 55
\BOOKMARK [2][-]{subsection.3.4.4}{Microbe-discovery methods}{section.3.4}% 56
\BOOKMARK [1][-]{section.3.5}{Computational issues}{chapter.3}% 57
\BOOKMARK [2][-]{subsection.3.5.1}{Alignment and assembly}{section.3.5}% 58
\BOOKMARK [2][-]{subsection.3.5.2}{mutations detection}{section.3.5}% 59
\BOOKMARK [2][-]{subsection.3.5.3}{Validation of mutation and rearrangement calls}{section.3.5}% 60
\BOOKMARK [0][-]{chapter.4}{Integrative genomics viewer}{part.2}% 61
\BOOKMARK [1][-]{section.4.1}{Introduction}{chapter.4}% 62
\BOOKMARK [0][-]{chapter.5}{Tumour heterogeneity and resistance to cancer therapies}{part.2}% 63
\BOOKMARK [1][-]{section.5.1}{Abstract}{chapter.5}% 64
\BOOKMARK [2][-]{subsection.5.1.1}{Introduction}{section.5.1}% 65
\BOOKMARK [1][-]{section.5.2}{Causes of intratumoral heterogeneity}{chapter.5}% 66
\BOOKMARK [2][-]{subsection.5.2.1}{Genomic instability}{section.5.2}% 67
\BOOKMARK [2][-]{subsection.5.2.2}{The clonal evolution and selection hypothesis}{section.5.2}% 68
\BOOKMARK [1][-]{section.5.3}{The spectrum of tumour heterogeneity}{chapter.5}% 69
\BOOKMARK [2][-]{subsection.5.3.1}{Spatial heterogeneity}{section.5.3}% 70
\BOOKMARK [2][-]{subsection.5.3.2}{Temporal heterogeneity}{section.5.3}% 71
